DENDRIGHT

Dendright is a clinical stage biopharmaceutical company commercializing an immune tolerizing immunotherapy for rheumatoid arthritis. The Company’ s technology targets dendritic cells that present and orchestrate the body’s immune responses to foreign and self-antigens. Dendright’s tolerizing immunotherapy acts to down regulate the immune system rather than to activate it, such that immune responses to given self-antigens are ‘turned off’. By targeting the cause of autoimmune disease rather than treating the symptoms, Dendright offers the potential for long-lasting treatment by working with the body’s own immune system to fight disease.